Phase I and Pharmacokinetic Study of Sequences

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kow...

0 downloads 0 Views 477KB Size

Recommend Documents

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

standard samples containing blank plasma spiked with prino- mastat and AG3473 were ... An API III Perkin-Elmer Sciex LC/MS using positive ion electrospray ...

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...

This regimen deserves further evaluation to define its antitumor activity .... DLT was defined as any of the ..... Karenitecin is the first compound of this type to be.

Dugan, M. A phase I study of SCH 52365 (temozolomide) in adult patients with .... Fletcher, W. S., Daniels, D. S., Sondak, V. K., Dana, B., Townsend,. R., Hynes ...

Department of Medicine [L. M. K., K. K. N., M. G. K., V. A. M.,. J. K.], Program of Molecular ... the Simon Benlevy Cancer Fund. 2 To whom requests for reprints ...

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

Apr 1, 1994 - nitrogen is believed to be the mechanism ... Doses of sodium phenylacetate to be infused over 30 min to 2 h were prepared in 150 ml .... posed of two pumps (305 and 306), an 805 manometric module, an 811C dynamic mixer ...

treatment of multiple myeloma, ovarian cancer, breast cancer, and neuroblastoma (3–5). .... ferases, -glutamyl-aminotransferase, alkaline phosphatase, and.

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

were no DLTs in the six patients evaluated at the first two dose levels of 600 and 900 g/m2. Reversible grade 4 transaminitis occurred in two of nine patients after ...

Apr 20, 2010 - Blood sampling for PK and drug-drug interaction studies was done. ... trabectedin every 2 weeks in patients with advanced solid tumors. J Clin.

In a phase 2 study of raltitrexed, cisplatin, and 5- fluorouracil administered to .... nitroacetanilide, was obtained from Sigma-Aldrich (Milwaukee,. WI). Twenty-five ...

Jun 3, 2018 - ... Ate van der Gaast,1 Andre¤ S.T. Planting,1 Leny van Doorn,1 Aletta Lems,1 ... of identifying novel anticancer agents in marine organisms.

Mar 1, 2008 - Elizabeth G. Trehu,5 David Schenkein,5 Donna Neuberg,3 Richard M. Stone,2 and Philip C. Amrein1. Abstract Purpose: ... sine (cytarabine, Ara-C), an antimetabolite cytotoxic primarily to cells in ...... Tallman MS. Therapy of ...

G. D.], Harvard Medical School, Boston, Massachusetts 02115, and. Clinical Research and .... Downloaded from .... serum chemistry determinations every 48–72 h until all param- .... reassayed upon dilution with drug-free human plasma. ...... Foye. (

Oct 13, 2009 - pared with prior studies of the parental antibody hu3S193. These results ... humanized monoclonal antibody based on the anti-Ley anti-.

Center, San Antonio, Texas 78284 ¡T.E. W.]; and Burroughs Wellcome Company, Research Triangle ... patients who were also monitored following a single i.v. dose of 140 and ... plasma concentration-time curve to be accurately predicted from the 3- ...